# EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|---|---|---|---|---|---|---|
| L1 | 5 | "6037347" | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT | OR | OFF | 2007/02/14 10:20 |
| L2 | 1873 | "aricept" or "donepezil" | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT | OR | OFF | 2007/02/14 10:20 |
| L3 | 0 | l2 near parkinson | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT | OR | OFF | 2007/02/14 10:20 |
| L4 | 969 | l2 and parkinson | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT | OR | OFF | 2007/02/14 10:21 |
| L5 | 19 | "aricept".clm. | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT | OR | OFF | 2007/02/14 10:21 |
| L6 | 14 | "aricept".clm. and "parkinson" | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT | OR | OFF | 2007/02/14 10:23 |
| L7 | 82 | "donepezil".clm. and "parkinson" | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT | OR | OFF | 2007/02/14 10:32 |
| L8 | 15 | "6087392" | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT | OR | OFF | 2007/02/14 12:05 |

# EAST Search History

| | | | | | | |
|---|---|---|---|---|---|---|
| L9 | 125 | "4,895,841" | US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT | OR | OFF | 2007/02/14 12:05 |

=> **file registry**

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.42 | 0.42 |

FILE 'REGISTRY' ENTERED AT 10:14:42 ON 14 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 FEB 2007 HIGHEST RN 920805-97-6
DICTIONARY FILE UPDATES: 13 FEB 2007 HIGHEST RN 920805-97-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10806409.str



chain nodes :
10 11 18 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42
43 44 45 46 47 48 49
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17 19 20 21 22 23 24
chain bonds :
1-28 2-26 3-25 4-27 7-10 8-11 8-31 9-29 9-30 11-12 11-32 11-33 12-34
13-35 13-36 14-37 14-38 15-18 16-39 16-40 17-41 17-42 18-19 18-43 18-44
20-45 21-46
22-47 23-48 24-49
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17 19-20 19-24 20-21 21-22 22-23 23-24
exact/norm bonds :
5-7 6-9 7-8 7-10 8-9 12-13 12-17 13-14 14-15 15-16 15-18 16-17
exact bonds :

1-28 2-26 3-25 4-27 8-11 8-31 9-29 9-30 11-12 11-32 11-33 12-34 13-35
13-36 14-37 14-38 16-39 16-40 17-41 17-42 18-19 18-43 18-44 20-45 21-46
22-47 23-48
24-49
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 19-20 19-24 20-21 21-22 22-23 23-24

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:Atom
20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS
40:CLASS 41:CLASS
42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS

L1 STRUCTURE UPLOADED

=> **d l1**
L1 HAS NO ANSWERS
L1 STR




Structure attributes must be viewed using STN Express query preparation.

=> **s l1**
SAMPLE SEARCH INITIATED 10:15:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED 20 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 132 TO 668
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> **d l2**

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
RN 880084-98-0 REGISTRY
ED Entered STN: 11 Apr 2006
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H29 N O3 . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

CM 1

CRN 120014-06-4
CMF C24 H29 N O3




CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l1 exa full
FULL SEARCH INITIATED 10:15:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 40 TO ITERATE

100.0% PROCESSED 40 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

L3 6 SEA EXA FUL L1

=> **d scan**

L3  6 ANSWERS  REGISTRY  COPYRIGHT 2007 ACS on STN
IN  1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI)
MF  C24 H29 N O3
CI  COM



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3  6 ANSWERS  REGISTRY  COPYRIGHT 2007 ACS on STN
IN  1H-Inden-1-one-2-14C, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI)
MF  C24 H29 N O3
CI  COM



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3  6 ANSWERS  REGISTRY  COPYRIGHT 2007 ACS on STN
IN  1H-Inden-1-one, 2,3-dihydro-6-methoxy-5-(methoxy-11C)-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI)
MF  C24 H29 N O3



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Inden-1-one, 2,3-dihydro-5-methoxy-6-(methoxy-11C)-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI)
MF C24 H29 N O3




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, (2R)- (9CI)
MF C24 H29 N O3
CI COM

Absolute stereochemistry.




**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-, (2S)- (9CI)
MF C24 H29 N O3
CI COM

Absolute stereochemistry.



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

ALL ANSWERS HAVE BEEN SCANNED

=> **file medline, caplus, wpids, uspatfull**

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 60.65 | 61.07 |

FILE 'MEDLINE' ENTERED AT 10:15:55 ON 14 FEB 2007

FILE 'CAPLUS' ENTERED AT 10:15:55 ON 14 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 10:15:55 ON 14 FEB 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 10:15:55 ON 14 FEB 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> **d his**

(FILE 'HOME' ENTERED AT 10:13:17 ON 14 FEB 2007)

FILE 'REGISTRY' ENTERED AT 10:14:42 ON 14 FEB 2007
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 6 S L1 EXA FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:15:55 ON 14 FEB 2007

=> **s l3**
SAMPLE SEARCH INITIATED 10:16:05 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED - 13 TO ITERATE

100.0% PROCESSED 13 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.02

| FULL FILE PROJECTIONS: | ONLINE | **COMPLETE** |
|---|---|---|
| | BATCH | **COMPLETE** |
| PROJECTED ITERATIONS: | 22 TO | 238 |
| PROJECTED ANSWERS: | 3 TO | 81 |

L4 919 L3

=> **s l4 not py>2000**
L5 96 L4 NOT PY>2000

=> **s l5 and parkinson**
L6 2 L5 AND PARKINSON

=> **d l6 1-2 ibib, abs, hitstr**

L6 ANSWER 1 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2000:31421 USPATFULL Full-text
TITLE: Combination preparation for use in dementia
INVENTOR(S): Schubert, Hans-Peter, Apfeldorf, Germany, Federal Republic of
Nimmesgern, Hildegard, Darmstadt, Germany, Federal Republic of
Rudolphi, Karl, Mainz, Germany, Federal Republic of
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6037347 | | 20000314 | |
| APPLICATION INFO.: | US 1998-30207 | | 19980225 | (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | DE 1997-19707655 | 19970226 |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gitomer, Ralph
ASSISTANT EXAMINER: Moran, Marjorie A.
LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 19
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a composition which is a pharmaceutical combination preparation comprising a compound which has an acetylcholinesterase-inhibitory action or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level, wherein the combination preparation is suitable for the treatment of dementia. The invention further relates to a process for the production of the combination preparation. The invention additionally relates to a process for treating patients in need of suitable therapy with the combination preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 120014-06-4
(combined preparation for treatment of dementia)
RN 120014-06-4 USPATFULL
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




L6 ANSWER 2 OF 2 USPATFULL on STN
ACCESSION NUMBER: 1999:155706 USPATFULL Full-text
TITLE: Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and

prophylactic uses thereof
INVENTOR(S): Gerolymatos, Panayotis N., Kryoneri Attikis, Greece
PATENT ASSIGNEE(S): P.N. Gerolymatos S.A., Kryoneri Attikis, Greece
(non-U.S. corporation)

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5994323 | | 19991130 |
| APPLICATION INFO.: | US 1998-23542 | | 19980213 (9) |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | GR 1997-970100507 | 19971231 |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1039
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical composition is disclosed that comprises clioquinol, vitamin B.sub.12, and, optionally, pharmaceutical acceptable carriers and/or excipients. The use of the pharmaceutical composition removes or alleviates the side effects of clioquinol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 120014-06-4, Donepezil
(phanquinone and other agents for the treatment of Alzheimer's disease)
RN 120014-06-4 USPATFULL
CN 1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




=> **s "donepezil" or "aricept"**
L7 4186 "DONEPEZIL" OR "ARICEPT"

=> **s l7 and "parkinson"**
L8 1061 L7 AND "PARKINSON"

=> **s l8 not py>2000**
L9 17 L8 NOT PY>2000

=> **d l9 1-17 ibib, abs**

L9 ANSWER 1 OF 17 MEDLINE on STN
ACCESSION NUMBER: 1999154200 MEDLINE Full-text

DOCUMENT NUMBER: PubMed ID: 10029938
TITLE: Donepezil for dementia with Lewy bodies: a case study.
AUTHOR: Aarsland D; Bronnick K; Karlsen K
SOURCE: International journal of geriatric psychiatry, (1999 Jan) Vol. 14, No. 1, pp. 69-72.
Journal code: 8710629. ISSN: 0885-6230.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: (CASE REPORTS)
Letter
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199904
ENTRY DATE: Entered STN: 11 May 1999
Last Updated on STN: 11 May 1999
Entered Medline: 23 Apr 1999

L9 ANSWER 2 OF 17 MEDLINE on STN
ACCESSION NUMBER: 1999028666 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 9812132
TITLE: Violent behavior-associated with donepezil.
AUTHOR: Bouman W P; Pinner G
SOURCE: The American journal of psychiatry, (1998 Nov) Vol. 155, No. 11, pp. 1626-7.
Journal code: 0370512. ISSN: 0002-953X.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS)
Letter
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 199811
ENTRY DATE: Entered STN: 6 Jan 1999
Last Updated on STN: 6 Jan 1999
Entered Medline: 23 Nov 1998

L9 ANSWER 3 OF 17 MEDLINE on STN
ACCESSION NUMBER: 1999001323 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 9785144
TITLE: Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients.
AUTHOR: Shea C; MacKnight C; Rockwood K
CORPORATE SOURCE: Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia Canada.
SOURCE: International psychogeriatrics / IPA, (1998 Sep) Vol. 10, No. 3, pp. 229-38.
Journal code: 9007918. ISSN: 1041-6102.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS)
(CLINICAL TRIAL)
(CONTROLLED CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199812
ENTRY DATE: Entered STN: 15 Jan 1999
Last Updated on STN: 3 Mar 2000
Entered Medline: 11 Dec 1998
AB Dementia with Lewy bodies (DLB) is common. Symptomatic treatment can be difficult. We reviewed nine consecutive patients with DLB (mean age 77.5 [range 67 to 84] years; seven men and two women; mean duration of disease 3.7

[range 1.5 to 8.0] years) who had been treated with donepezil . Each initially received 2.5 to 5 mg per day of donepezil, and was stabilized on 5 mg per day. Donepezil was increased to 10 mg per day in five patients. The mean observation period was 12 (range 8 to 24) weeks. Target symptoms included cognition, hallucinations, parkinsonism, and functional abilities. By both cognitive testing and family reports, cognition improved in seven of nine patients, remained the same in one of nine, and fluctuated in one of nine (mean Mini-Mental State Examination change 4.4 +/- 6.3 points). Function was improved or maintained in six of nine patients and fluctuated in two of nine. Hallucinations initially worsened, then fluctuated in one patient, but improvement in frequency, duration, and content was reported in eight of nine cases. In three of nine patients, treatment with donepezil resulted in worsening of parkinsonism, which in each case responded to levodopa/carbidopa. Treatment of DLB patients with donepezil for 12 weeks most commonly improved hallucinations, and sometimes improved cognition and overall function. Treatment with donepezil was sometimes associated with worse parkinsonism.

L9 ANSWER 4 OF 17 MEDLINE on STN
ACCESSION NUMBER: 1998456516 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 9783187
TITLE: [50th Annual Meeting of the American Academy of Neurology (AAN). Minneapolis, 25 April--2 May 1998. 151st Annual Meeting of the American Psychiatric Association (APA). Toronto, 31 May--3 June 1998].
50th Annual Meeting of the American Academy of Neurology (AAN) Minneapolis, 25. April bis 2. Mai 1998. 151st Annual Meeting of the American Psychiatric Association (APA) Toronto, 31. Mai bis 3. Juni 1998.
AUTHOR: Anonymous
SOURCE: Fortschritte der Neurologie-Psychiatrie, (1998 Sep) Vol. 66, No. 9 Suppl, pp. 1-8.
Journal code: 8103137. ISSN: 0720-4299.
PUB. COUNTRY: GERMANY: Germany, Federal Republic of
DOCUMENT TYPE: Conference; Conference Article; (CONGRESSES)
LANGUAGE: German
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199810
ENTRY DATE: Entered STN: 6 Jan 1999
Last Updated on STN: 6 Jan 1999
Entered Medline: 27 Oct 1998

L9 ANSWER 5 OF 17 MEDLINE on STN
ACCESSION NUMBER: 1998269331 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 9606486
TITLE: Possible association between donepezil and worsening Parkinson's disease.
AUTHOR: Bourke D; Druckenbrod R W
SOURCE: The Annals of pharmacotherapy, (1998 May) Vol. 32, No. 5, pp. 610-1.
Journal code: 9203131. ISSN: 1060-0280.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS)
Letter
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199807
ENTRY DATE: Entered STN: 11 Aug 1998
Last Updated on STN: 11 Aug 1998
Entered Medline: 30 Jul 1998

L9 ANSWER 6 OF 17 MEDLINE on STN
ACCESSION NUMBER: 1998260645 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 9598283
TITLE: Combination of risperidone and donepezil in Lewy body dementia.
AUTHOR: Geizer M; Ancill R J
SOURCE: Canadian journal of psychiatry. Revue canadienne de psychiatrie, (1998 May) Vol. 43, No. 4, pp. 421-2. Journal code: 7904187. ISSN: 0706-7437.
PUB. COUNTRY: Canada
DOCUMENT TYPE: (CASE REPORTS)
Letter
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199808
ENTRY DATE: Entered STN: 20 Aug 1998
Last Updated on STN: 20 Aug 1998
Entered Medline: 10 Aug 1998

L9 ANSWER 7 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2000:174658 USPATFULL Full-text
TITLE: Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
INVENTOR(S): Viner, Norman, Ottawa, Canada
PATENT ASSIGNEE(S): Synapse Pharmaceuticals International, Inc., Ottawa, Canada (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6166032 | | 20001226 | |
| APPLICATION INFO.: | US 1997-797251 | | 19970207 | (8) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
LINE COUNT: 611
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for controlling tobacco use and alleviating withdrawal symptoms due to the cessation of tobacco use comprising administering to a human desiring to control tobacco use and/or suffering from withdrawal due to cessation of such use an effective amount of an acetylcholine esterase reactivator or prodrug derivative thereof optionally in association with an acetylcholine receptor antagonist.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2000:169089 USPATFULL Full-text
TITLE: Method and apparatus for treating chronic pain syndromes, tremor, dementia and related disorders and for inducing electroanesthesia using high frequency, high intensity transcutaneous electrical nerve stimulation
INVENTOR(S): Silverstone, Leon M., La Jolla, CA, United States
PATENT ASSIGNEE(S): Synaptic Corporation, Aurora, CO, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6161044 | | 20001212 | |
| APPLICATION INFO.: | US 1998-199073 | | 19981123 | (9) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kamm, William E.
LEGAL REPRESENTATIVE: Fitch, Even, Tabin & Flannery
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1249

AB Provided herein is a non-invasive method of treating, controlling or preventing medical, psychiatric or neurological disorders, using transcutaneous electrical stimulation. The method employs a plurality of stimulation frequency parameters, ranging from a relatively high frequency, for example about 40,000 Hertz, to a relatively low frequency, for example about 250 Hertz, the entire plurality of frequency parameters being administered at each of a plurality of stimulation intensity levels. In particular, the method involves stimulating at a first highest frequency parameter and a first lowest intensity parameter, incrementally decreasing the stimulation frequency parameter a lowest frequency parameter, increasing the frequency parameter to the highest frequency parameter and increasing the intensity parameter to a next highest intensity parameter, and again stimulating through the plurality of frequency parameters from the highest frequency to the lowest frequency. The method described herein is useful in treating, controlling and/or preventing various disease states and disorders, including without limitation, tremor disorders, such as essential tremor and Parkinson's disease, dementia disorders, such as Alzheimer's disease and painful degenerative disorders, such as reflex sympathetic dystrophy and fibromyalgia.

L9 ANSWER 9 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2000:164554 USPATFULL Full-text
TITLE: Cyclobutyl-aryloxyarylsulfonylamino hydroxamic acid derivatives
INVENTOR(S): Reiter, Lawrence A., Mystic, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc, New York, NY, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6156798 | | 20001205 | |
| APPLICATION INFO.: | US 1999-290023 | | 19990409 | (9) |

| | NUMBER | DATE | |
|---|---|---|---|
| PRIORITY INFORMATION: | US 1998-81392P | 19980410 | (60) |
| | US 1997-55208P | 19970808 | (60) |
| | US 1997-55207P | 19970808 | (60) |
| | US 1997-62766P | 19971024 | (60) |
| | US 1997-68261P | 19971219 | (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Davis, Brian J.
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Jacobs, Seth

H.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1142
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula ##STR1## wherein Y and R.sup.1 are defined in the specification, useful in the treatment of arthritis or cancer and other diseases involving selective inhibition of matrix metalloproteinase-13.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2000:128350 USPATFULL Full-text
TITLE: Diphenylalkyl-tetrahydropyridines, process for their preparation, and pharmaceutical compositions containing them
INVENTOR(S): Baroni, Marco, Vanzago, Italy
Cardamone, Rosanna, Como, Italy
Fournier, Jacqueline, Plaisance du Touch, France
Guzzi, Umberto, Milan, Italy
PATENT ASSIGNEE(S): Sanofi-Synthelabo, Paris, France (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6124318 | | 20000926 | |
| | WO 9825904 | | 19980618 | |
| APPLICATION INFO.: | US 1999-331005 | | 19990727 | (9) |
| | WO 1997-FR2289 | | 19971211 | |
| | | | 19990727 | PCT 371 date |
| | | | 19990727 | PCT 102(e) date |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | FR 1996-15336 | 19961213 |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Seaman, D. Margaret
LEGAL REPRESENTATIVE: Alexander, Michael D., Dupont, Paul E.
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
LINE COUNT: 748
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compounds of the formula ##STR1## in which: Y is --CH-- or --N--;

R.sub.1 is a halogen or a CF.sub.3, (C.sub.1 -C.sub.4)alkyl or (C.sub.1 -C.sub.4)alkoxy group;

R.sub.2 and R.sub.3 are each hydrogen or a (C.sub.1 -C.sub.3)alkyl;

n is 0 or 1; and

Ph.sub.1 and Ph.sub.2 are each independently an unsubstituted, monosubstituted or polysubstituted phenyl group;

to a process for their preparation and to the pharmaceutical compositions containing them.

These compounds have neurotrophic and neuroprotective activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 17 USPATFULL on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2000:124824 USPATFULL Full-text |
| TITLE: | Synthetic antisense oligodeoxynucleotides targeted to human ache |
| INVENTOR(S): | Soreq, Hermona, Jerusalem, Israel<br>Seidman, Shlomo, Neve Daniel, Israel<br>Eckstein, Fritz, Gottingen, Germany, Federal Republic of<br>Friedman, Alon, M. Post HaNeguev, Israel<br>Kaufer, Daniela, Mevasseret Zion, Israel |
| PATENT ASSIGNEE(S): | Yissum Research Development Company of the Hebrew Yniversity of Jerusalem, Jerusalem, Israel (non-U.S. corporation) |

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 6121046 | | 20000919 |
| APPLICATION INFO.: | US 1997-990065 | | 19971212 (8) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. US 1997-850347, filed on 2 May 1997 which is a continuation-in-part of Ser. No. US 318826 | | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1996-35266P | 19961212 (60) |
| | US 1997-37777P | 19970213 (60) |
| | US 1997-53334P | 19970721 (60) |

| | |
|---|---|
| DOCUMENT TYPE: | Utility |
| FILE SEGMENT: | Granted |
| PRIMARY EXAMINER: | LeGuyader, John L. |
| ASSISTANT EXAMINER: | Lacourciere, Karen A. |
| LEGAL REPRESENTATIVE: | Kohn & Associates |
| NUMBER OF CLAIMS: | 14 |
| EXEMPLARY CLAIM: | 1 |
| NUMBER OF DRAWINGS: | 12 Drawing Figure(s); 12 Drawing Page(s) |
| LINE COUNT: | 2796 |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A synthetic nuclease resistant antisense oligodeoxynucleotide (AS-ODN) capable of selectively modulating human acetylcholinesterase (AChE) production and a composition comprising at least one AS-ODN as an active ingredient. A nuclease resistant antisense targeted against the splice junction in the AChE mRNA post-splice message is disclosed. The synthetic nuclease resistant AS-ODNs are capable of selectively modulating human AChE production in the central nervous system or capable of selectively reducing human AChE deposition of the neuromuscular junction. The present invention also provides a method to restore balanced cholinergic signalling in the brain and spinal cord or reduce AChE in the neuromuscular junction in patients in need of such treatment by administering to a patient in need of such treatment a therapeutically effective amount of at least one of the

synthetic nuclease resistant AS-ODN capable of selectively modulating human AChE production.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 17 USPATFULL on STN

| | | | |
|---|---|---|---|
| ACCESSION NUMBER: | 2000:117742 USPATFULL Full-text | | |
| TITLE: | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives | | |
| INVENTOR(S): | Robinson, Ralph P., Gales Ferry, CT, United States<br>Laird, Ellen R., Mystic, CT, United States | | |
| PATENT ASSIGNEE(S): | Pfizer Inc., New York, NY, United States (U.S. corporation) | | |
| | NUMBER | KIND | DATE |
| PATENT INFORMATION: | US 6114361 | | 20000905 |
| APPLICATION INFO.: | US 1999-429937 | | 19991029 (9) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | McKane, Joseph | | |
| ASSISTANT EXAMINER: | Oswecki, Jane C. | | |
| LEGAL REPRESENTATIVE: | Richardson, Peter C., Ginsburg, Paul H., Jacobs, Seth | | |
| NUMBER OF CLAIMS: | 19 | | |
| EXEMPLARY CLAIM: | 1 | | |
| LINE COUNT: | 1761 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a compound of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 are as defined above, to pharmaceutical compositions and methods of treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 17 USPATFULL on STN

| | | | |
|---|---|---|---|
| ACCESSION NUMBER: | 2000:113991 USPATFULL Full-text | | |
| TITLE: | Bicyclic hydroxamic acid derivatives | | |
| INVENTOR(S): | Robinson, Ralph Pelton, Gales Ferry, CT, United States | | |
| PATENT ASSIGNEE(S): | Pfizer Inc., New York, NY, United States (U.S. corporation) | | |
| | NUMBER | KIND | DATE |
| PATENT INFORMATION: | US 6110964 | | 20000829 |
| | WO 9952910 | | 19991021 |
| APPLICATION INFO.: | US 1999-402259 | | 19990930 (9) |
| | WO 1999-IB503 | | 19990324 |
| | | | 19990930 PCT 371 date |
| | | | 19990930 PCT 102(e) date |
| | NUMBER | | DATE |
| PRIORITY INFORMATION: | US 1998-81309P | | 19980410 (60) |
| | US 1997-55208P | | 19970808 (60) |
| | US 1997-55207P | | 19970808 (60) |
| | US 1997-62766P | | 19971024 (60) |
| | US 1997-68261P | | 19971219 (60) |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |

PRIMARY EXAMINER: Lambkin, Deborah C.
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Appleman, Polene W.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
LINE COUNT: 1851
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula ##STR1## wherein Z and Q are as defined in the specification, to pharmaceutical compositions containing them and to their medicinal use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2000:88221 USPATFULL Full-text
TITLE: (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
INVENTOR(S): Reiter, Lawrence Alan, Mystic, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6087392 | | 20000711 | |
| | WO 9952889 | | 19991021 | |
| APPLICATION INFO.: | US 1999-380436 | | 19990901 | (9) |
| | WO 1999-IB505 | | 19990324 | |
| | | | 19990901 | PCT 371 date |
| | | | 19990901 | PCT 102(e) date |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | US 1998-81364P | 19980410 (60) |
| | US 1997-55208P | 19970808 (60) |
| | US 1997-55207P | 19970808 (60) |
| | US 1997-62766P | 19971024 (60) |
| | US 1997-68261P | 19971219 (60) |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Butterfield, Garth
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 1377
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula ##STR1## wherein Q is as defined above, are useful in the treatment of a condition selected from the group consisting of arthritis (including osteoarthritis and rheumatoid arthritis), inflammatory bowel disease, Crohn's disease, emphysema, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant toxicity, cachexia, allergic reactions, allergic contact hypersensitivity, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, loosening of artificial joint implants, atherosclerosis (including atherosclerotic plaque rupture), aortic aneurysm (including abdominal aortic aneurysm and brain aortic aneurysm), congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, spinal cord injury, neuro-degenerative disorders (acute and chronic), autoimmune disorders, Huntington's disease, Parkinson's disease, migraine, depression, peripheral

neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, abnormal wound healing, burns, diabetes, tumor invasion, tumor growth, tumor metastasis, corneal scarring, scleritis, AIDS, sepsis and septic shock. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 17 USPATFULL on STN

| | | | |
|---|---|---|---|
| ACCESSION NUMBER: | 2000:31421 USPATFULL Full-text | | |
| TITLE: | Combination preparation for use in dementia | | |
| INVENTOR(S): | Schubert, Hans-Peter, Apfeldorf, Germany, Federal Republic of<br>Nimmesgern, Hildegard, Darmstadt, Germany, Federal Republic of<br>Rudolphi, Karl, Mainz, Germany, Federal Republic of | | |
| PATENT ASSIGNEE(S): | Hoechst Aktiengesellschaft, Frankfurt am Main, Germany, Federal Republic of (non-U.S. corporation) | | |
| | NUMBER | KIND | DATE |
| PATENT INFORMATION: | US 6037347 | | 20000314 |
| APPLICATION INFO.: | US 1998-30207 | | 19980225 (9) |
| | NUMBER | | DATE |
| PRIORITY INFORMATION: | DE 1997-19707655 | | 19970226 |
| DOCUMENT TYPE: | Utility | | |
| FILE SEGMENT: | Granted | | |
| PRIMARY EXAMINER: | Gitomer, Ralph | | |
| ASSISTANT EXAMINER: | Moran, Marjorie A. | | |
| LEGAL REPRESENTATIVE: | Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. | | |
| NUMBER OF CLAIMS: | 21 | | |
| EXEMPLARY CLAIM: | 19 | | |
| NUMBER OF DRAWINGS: | 3 Drawing Figure(s); 3 Drawing Page(s) | | |
| LINE COUNT: | 543 | | |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a composition which is a pharmaceutical combination preparation comprising a compound which has an acetylcholinesterase-inhibitory action or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level, wherein the combination preparation is suitable for the treatment of dementia. The invention further relates to a process for the production of the combination preparation. The invention additionally relates to a process for treating patients in need of suitable therapy with the combination preparation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 17 USPATFULL on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2000:27986 USPATFULL Full-text |
| TITLE: | 1-Phenylalkyl-1,2,3,6-tetrahydropyridines for treating Alzheimer's disease |
| INVENTOR(S): | Baroni, Marco, Vanzago, Italy |

Cardamone, Rosanna, Como, Italy
Fournier, Jacqueline, Plaisance Du Touch, France
Guzzi, Umberto, Milan, Italy
PATENT ASSIGNEE(S): Sanofi-Synthlabo, Paris, France (non-U.S. corporation)

| | NUMBER | KIND | DATE | |
|---|---|---|---|---|
| PATENT INFORMATION: | US 6034090 | | 20000307 | |
| | WO 9825903 | | 19980618 | |
| APPLICATION INFO.: | US 1999-331006 | | 19990727 | (9) |
| | WO 1997-FR2286 | | 19971212 | |
| | | | 19990727 | PCT 371 date |
| | | | 19990727 | PCT 102(e) date |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | FR 1996-15335 | 19961213 |

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davis, Zinna Northington
ASSISTANT EXAMINER: Robinson, Binta
LEGAL REPRESENTATIVE: Alexander, Michael D.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 791
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds of the formula in which: Y is --CH-- or --N--; R.sub.1 is hydrogen, a halogen or a CF.sub.3, (C.sub.1 -C.sub.4)alkyl or (C.sub.1 -C.sub.4)alkoxy group; R.sub.2 is a methyl or ethyl group; R.sub.3 and R.sub.4 are each hydrogen or a (C.sub.1 -C.sub.3)alkyl; and X is:

(a) a (C.sub.1 -C.sub.6)alkyl, a (C.sub.1 -C.sub.6)alkoxy, a (C.sub.3 -C.sub.7)carboxyalkyl, a (C.sub.1 -C.sub.4)alkoxy-carbonyl(C.sub.1 -C.sub.6)alkyl, a (C.sub.3 -C.sub.7)carboxyalkoxy or a (C.sub.1 -C.sub.4)alkoxycarbonyl-(C.sub.1 -C.sub.6)alkoxy;

(b) a radical selected from (C.sub.3 -C.sub.7)cycloalkyl, (C.sub.3 -C.sub.7)cycloalkoxy, (C.sub.3 -C.sub.7)-cycloalkylmethyl, (C.sub.3 -C.sub.7)cycloalkylamino and cyclohexenyl, it being possible for said radical to be substituted by a halogen, hydroxyl, (C.sub.1 -C.sub.4)-alkoxy, carboxyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, amino or mono- or di-(C.sub.1 -C.sub.4)-alkylamino; or

(c) a group selected from a phenyl, phenoxy, phenylamino, N-(C.sub.1 -C.sub.3)alkyl-phenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl and styryl, it being possible for said group to be monosubstituted or polysubstituted on the phenyl group by a halogen, CF.sub.3, (C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxy, cyano, amino, mono- or di-(C.sub.1 -C.sub.4)alkyl- amino, (C.sub.1 -C.sub.4)acylamino, carboxyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, aminocarbonyl, mono- or di-(C.sub.1 -C.sub.4)alkylaminocarbonyl, amino(C.sub.1 -C.sub.4)alkyl, hydroxy(C.sub.1 -C.sub.4)alkyl or halogeno(C.sub.1 -C.sub.4)alkyl;

to a method of preparing them and to the pharmaceutical compositions containing them. These compounds have neurotrophic and neuroprotective activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 17 USPATFULL on STN

| | |
|---|---|
| ACCESSION NUMBER: | 1999:121436 USPATFULL Full-text |
| TITLE: | Composition for alzheimer's disease |
| INVENTOR(S): | Miyamoto, Masaomi, Hyogo, Japan<br>Ohta, Hiroyuki, Osaka, Japan<br>Goto, Giichi, Osaka, Japan |
| PATENT ASSIGNEE(S): | Takeda Chemical Industries, Ltd., Osaka, Japan<br>(non-U.S. corporation) |

| | NUMBER | KIND | DATE |
|---|---|---|---|
| PATENT INFORMATION: | US 5962535 | | 19991005 |
| APPLICATION INFO.: | US 1998-42625 | | 19980317 (9) |
| RELATED APPLN. INFO.: | Continuation-in-part of Ser. No. WO 1998-JP109, filed on 14 Jan 1998 | | |

| | NUMBER | DATE |
|---|---|---|
| PRIORITY INFORMATION: | JP 1997-6147 | 19970117 |
| | US 1997-65597P | 19971118 (60) |

| | |
|---|---|
| DOCUMENT TYPE: | Utility |
| FILE SEGMENT: | Granted |
| PRIMARY EXAMINER: | Criares, Theodore J. |
| LEGAL REPRESENTATIVE: | Wenderoth, Lind & Ponack, L.L.P. |
| NUMBER OF CLAIMS: | 5 |
| EXEMPLARY CLAIM: | 1 |
| NUMBER OF DRAWINGS: | 4 Drawing Figure(s); 4 Drawing Page(s) |
| LINE COUNT: | 878 |

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition comprising idebenone in combination with a compound having acetylcholinesterase inhibitory activity is useful for treating or preventing Alzheimer's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> FIL STNGUIDE

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 97.28 | 158.35 |

FILE 'STNGUIDE' ENTERED AT 10:33:11 ON 14 FEB 2007


FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 9, 2007 (20070209/UP).

=>
=> d his

```
     (FILE 'HOME' ENTERED AT 10:13:17 ON 14 FEB 2007)

     FILE 'REGISTRY' ENTERED AT 10:14:42 ON 14 FEB 2007
L1                STRUCTURE UPLOADED
L2              1 S L1
L3              6 S L1 EXA FULL

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:15:55 ON 14 FEB
     2007
L4            919 S L3
L5             96 S L4 NOT PY>2000
L6              2 S L5 AND PARKINSON
L7           4186 S "DONEPEZIL" OR "ARICEPT"
L8           1061 S L7 AND "PARKINSON"
L9             17 S L8 NOT PY>2000

     FILE 'STNGUIDE' ENTERED AT 10:33:11 ON 14 FEB 2007

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 2.28     160.63

STN INTERNATIONAL LOGOFF AT 10:56:16 ON 14 FEB 2007
```

- Search History will be lost after eight hours of inactivity.
- Search numbers may not be continuous; all searches are represented.
- To save search indefinitely, click query # and select Save in My NCBI.
- To combine searches use #search, e.g., #2 AND #3 or click query # for more options.

| Search | Most Recent Queries | Time | Result |
|---|---|---|---|
| #9 | Search **aricept and parkinson** | 10:56:09 | 32 |
| #1 | Search **donepezil and parkinson** | 10:55:33 | 42 |

Clear History

About Entrez
Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central